.png){kind=icon}
.png){kind=icon}
Return
Inducing Hypermutability to Promote Anti-PD-1 Therapy Response
.png){kind=icon}
PRE
AI
DOI：10.1158/2159-8290.CD-22-0492.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
The lack of clinical activity from various immune-checkpoint blockade approaches in mismatch repair-proficient (MMRp) colorectal cancer has demonstrated a critical need for novel approaches. In this issue, Crisafulli and colleagues provide proof of concept for the induction of hypermutability through the use of temozolomide as a potential pathway for enabling a productive anti-PD-1 immune response in MMRp colorectal cancer.
Keywords:
HYPERMUTATION
MSH6